Along these lines, we set out to more deeply characterize the mechanism(s) which proscribe the concurrence of BRAF(pV600E) and NRAS(pQ61) mutations in melanoma with an eye towards novel pathways which could countermand constitutive BRAF or NRAS signaling. The gene discussed is BRAF; the disease is melanoma.